Trials / Completed
CompletedNCT00559299
Patient Tolerability Study of GSK163090
A Randomized, Single-blind, Placebo-controlled, 2 Part Study to Evaluate the Safety and Tolerability of GSK163090 at Single and Repeat Doses in Subjects With MDD
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 20 (estimated)
- Sponsor
- GlaxoSmithKline · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine the safety and tolerability of a new drug, GSK163090, which is being developed for the treatment of depression and anxiety disorders.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | GSK163090 |
Timeline
- Start date
- 2007-11-01
- Primary completion
- 2008-06-01
- Completion
- 2008-06-01
- First posted
- 2007-11-16
- Last updated
- 2012-03-19
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00559299. Inclusion in this directory is not an endorsement.